In the closing of the recent trading day, Merck (MRK) stood at $94.02, denoting a -0.74% change from the preceding trading day.

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Jimmy Investor. In this article, we will summarize ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

Merck's stock dropped 1.37% in the latest session, underperforming the S&P 500’s 0.49% gain. Despite this, Merck has surged 9 ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Dividend-paying stocks are a traditional defensive play, while healthcare faces fewer trade and economic headwinds than most ...